IBDEI078 ; ; 01-MAY-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 01, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17608,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,17608,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,17608,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,17609,0)
 ;;=C92.40^^65^769^20
 ;;^UTILITY(U,$J,358.3,17609,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17609,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,17609,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,17609,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,17610,0)
 ;;=D56.0^^65^769^21
 ;;^UTILITY(U,$J,358.3,17610,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17610,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,17610,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,17610,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,17611,0)
 ;;=D63.1^^65^769^23
 ;;^UTILITY(U,$J,358.3,17611,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17611,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,17611,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,17611,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,17612,0)
 ;;=D63.0^^65^769^24
 ;;^UTILITY(U,$J,358.3,17612,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17612,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,17612,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,17612,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,17613,0)
 ;;=D63.8^^65^769^22
 ;;^UTILITY(U,$J,358.3,17613,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17613,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,17613,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,17613,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,17614,0)
 ;;=C22.3^^65^769^27
 ;;^UTILITY(U,$J,358.3,17614,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17614,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,17614,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,17614,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,17615,0)
 ;;=D61.9^^65^769^28
 ;;^UTILITY(U,$J,358.3,17615,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17615,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,17615,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,17615,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,17616,0)
 ;;=D56.1^^65^769^30
 ;;^UTILITY(U,$J,358.3,17616,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17616,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,17616,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,17616,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,17617,0)
 ;;=C83.79^^65^769^32
 ;;^UTILITY(U,$J,358.3,17617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17617,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17617,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,17617,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,17618,0)
 ;;=C83.70^^65^769^33
 ;;^UTILITY(U,$J,358.3,17618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17618,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,17618,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,17618,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,17619,0)
 ;;=D09.0^^65^769^40
 ;;^UTILITY(U,$J,358.3,17619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17619,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,17619,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,17619,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,17620,0)
 ;;=D06.9^^65^769^41
 ;;^UTILITY(U,$J,358.3,17620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17620,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,17620,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,17620,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,17621,0)
 ;;=D06.0^^65^769^43
 ;;^UTILITY(U,$J,358.3,17621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17621,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,17621,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,17621,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,17622,0)
 ;;=D06.1^^65^769^44
 ;;^UTILITY(U,$J,358.3,17622,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17622,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,17622,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,17622,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,17623,0)
 ;;=D06.7^^65^769^42
 ;;^UTILITY(U,$J,358.3,17623,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17623,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,17623,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,17623,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,17624,0)
 ;;=D04.9^^65^769^45
 ;;^UTILITY(U,$J,358.3,17624,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17624,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,17624,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,17624,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,17625,0)
 ;;=C91.11^^65^769^48
 ;;^UTILITY(U,$J,358.3,17625,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17625,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,17625,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,17625,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,17626,0)
 ;;=C91.10^^65^769^49
 ;;^UTILITY(U,$J,358.3,17626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17626,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,17626,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,17626,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,17627,0)
 ;;=C92.11^^65^769^50
 ;;^UTILITY(U,$J,358.3,17627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17627,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,17627,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,17627,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,17628,0)
 ;;=C92.10^^65^769^51
 ;;^UTILITY(U,$J,358.3,17628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17628,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,17628,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,17628,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,17629,0)
 ;;=D47.1^^65^769^52
 ;;^UTILITY(U,$J,358.3,17629,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17629,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,17629,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,17629,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,17630,0)
 ;;=C82.69^^65^769^53
 ;;^UTILITY(U,$J,358.3,17630,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17630,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17630,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,17630,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,17631,0)
 ;;=C82.60^^65^769^54
 ;;^UTILITY(U,$J,358.3,17631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17631,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,17631,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,17631,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,17632,0)
 ;;=D56.2^^65^769^55
 ;;^UTILITY(U,$J,358.3,17632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17632,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,17632,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,17632,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,17633,0)
 ;;=D75.9^^65^769^56
 ;;^UTILITY(U,$J,358.3,17633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17633,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,17633,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,17633,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,17634,0)
 ;;=D59.0^^65^769^59
 ;;^UTILITY(U,$J,358.3,17634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17634,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,17634,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,17634,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,17635,0)
 ;;=D59.2^^65^769^60
 ;;^UTILITY(U,$J,358.3,17635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17635,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,17635,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,17635,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,17636,0)
 ;;=R59.9^^65^769^63
 ;;^UTILITY(U,$J,358.3,17636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17636,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,17636,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,17636,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,17637,0)
 ;;=D47.3^^65^769^64
 ;;^UTILITY(U,$J,358.3,17637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17637,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,17637,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,17637,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,17638,0)
 ;;=C82.09^^65^769^65
 ;;^UTILITY(U,$J,358.3,17638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17638,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17638,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,17638,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,17639,0)
 ;;=C82.00^^65^769^66
 ;;^UTILITY(U,$J,358.3,17639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17639,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,17639,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,17639,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,17640,0)
 ;;=C82.19^^65^769^67
 ;;^UTILITY(U,$J,358.3,17640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17640,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17640,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,17640,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,17641,0)
 ;;=C82.10^^65^769^68
 ;;^UTILITY(U,$J,358.3,17641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17641,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,17641,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,17641,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,17642,0)
 ;;=C82.29^^65^769^69
 ;;^UTILITY(U,$J,358.3,17642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17642,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17642,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,17642,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,17643,0)
 ;;=C82.20^^65^769^70
 ;;^UTILITY(U,$J,358.3,17643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17643,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,17643,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,17643,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,17644,0)
 ;;=C82.39^^65^769^71
 ;;^UTILITY(U,$J,358.3,17644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17644,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17644,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,17644,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,17645,0)
 ;;=C82.30^^65^769^72
 ;;^UTILITY(U,$J,358.3,17645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17645,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,17645,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,17645,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,17646,0)
 ;;=C82.49^^65^769^73
 ;;^UTILITY(U,$J,358.3,17646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17646,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17646,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,17646,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,17647,0)
 ;;=C82.40^^65^769^74
 ;;^UTILITY(U,$J,358.3,17647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17647,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,17647,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,17647,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,17648,0)
 ;;=C82.99^^65^769^75
 ;;^UTILITY(U,$J,358.3,17648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17648,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17648,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,17648,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,17649,0)
 ;;=C82.90^^65^769^76
 ;;^UTILITY(U,$J,358.3,17649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17649,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,17649,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,17649,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,17650,0)
 ;;=R59.1^^65^769^61
 ;;^UTILITY(U,$J,358.3,17650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17650,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,17650,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,17650,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,17651,0)
 ;;=C91.40^^65^769^80
 ;;^UTILITY(U,$J,358.3,17651,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17651,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,17651,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,17651,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,17652,0)
 ;;=C91.42^^65^769^78
 ;;^UTILITY(U,$J,358.3,17652,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17652,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,17652,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,17652,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,17653,0)
 ;;=C91.41^^65^769^79
 ;;^UTILITY(U,$J,358.3,17653,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17653,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,17653,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,17653,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,17654,0)
 ;;=D57.01^^65^769^81
 ;;^UTILITY(U,$J,358.3,17654,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17654,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,17654,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,17654,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,17655,0)
 ;;=D57.00^^65^769^82
 ;;^UTILITY(U,$J,358.3,17655,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17655,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,17655,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,17655,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,17656,0)
 ;;=D57.02^^65^769^83
 ;;^UTILITY(U,$J,358.3,17656,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17656,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,17656,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,17656,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,17657,0)
 ;;=D68.32^^65^769^85
 ;;^UTILITY(U,$J,358.3,17657,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17657,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,17657,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,17657,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,17658,0)
 ;;=C22.2^^65^769^86
 ;;^UTILITY(U,$J,358.3,17658,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17658,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,17658,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,17658,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,17659,0)
 ;;=D58.9^^65^769^88
 ;;^UTILITY(U,$J,358.3,17659,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17659,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,17659,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,17659,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,17660,0)
 ;;=C81.99^^65^769^89
 ;;^UTILITY(U,$J,358.3,17660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17660,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17660,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,17660,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,17661,0)
 ;;=C81.90^^65^769^90
 ;;^UTILITY(U,$J,358.3,17661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17661,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,17661,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,17661,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,17662,0)
 ;;=D89.2^^65^769^91
 ;;^UTILITY(U,$J,358.3,17662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17662,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,17662,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,17662,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,17663,0)
 ;;=D05.12^^65^769^94
 ;;^UTILITY(U,$J,358.3,17663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17663,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,17663,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,17663,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,17664,0)
 ;;=D05.11^^65^769^95
 ;;^UTILITY(U,$J,358.3,17664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17664,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,17664,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,17664,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,17665,0)
 ;;=D05.10^^65^769^96
 ;;^UTILITY(U,$J,358.3,17665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17665,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,17665,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,17665,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,17666,0)
 ;;=D50.0^^65^769^97
 ;;^UTILITY(U,$J,358.3,17666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17666,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,17666,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,17666,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,17667,0)
 ;;=D50.9^^65^769^98
 ;;^UTILITY(U,$J,358.3,17667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17667,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,17667,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,17667,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,17668,0)
 ;;=C46.9^^65^769^99
 ;;^UTILITY(U,$J,358.3,17668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17668,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,17668,1,4,0)
 ;;=4^C46.9
 ;;^UTILITY(U,$J,358.3,17668,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,17669,0)
 ;;=C22.0^^65^769^100
 ;;^UTILITY(U,$J,358.3,17669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17669,1,3,0)
 ;;=3^Liver Cell Carcinoma
 ;;^UTILITY(U,$J,358.3,17669,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,17669,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,17670,0)
 ;;=D05.02^^65^769^101
 ;;^UTILITY(U,$J,358.3,17670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17670,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,17670,1,4,0)
 ;;=4^D05.02
 ;;^UTILITY(U,$J,358.3,17670,2)
 ;;=^5001928
 ;;^UTILITY(U,$J,358.3,17671,0)
 ;;=D05.01^^65^769^102
 ;;^UTILITY(U,$J,358.3,17671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17671,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,17671,1,4,0)
 ;;=4^D05.01
 ;;^UTILITY(U,$J,358.3,17671,2)
 ;;=^5001927
 ;;^UTILITY(U,$J,358.3,17672,0)
 ;;=D05.00^^65^769^103
 ;;^UTILITY(U,$J,358.3,17672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17672,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,17672,1,4,0)
 ;;=4^D05.00
 ;;^UTILITY(U,$J,358.3,17672,2)
 ;;=^5001926
 ;;^UTILITY(U,$J,358.3,17673,0)
 ;;=R59.0^^65^769^62
 ;;^UTILITY(U,$J,358.3,17673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17673,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Localized
 ;;^UTILITY(U,$J,358.3,17673,1,4,0)
 ;;=4^R59.0
 ;;^UTILITY(U,$J,358.3,17673,2)
 ;;=^5019529
 ;;^UTILITY(U,$J,358.3,17674,0)
 ;;=C83.59^^65^769^104
 ;;^UTILITY(U,$J,358.3,17674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17674,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,17674,1,4,0)
 ;;=4^C83.59
 ;;^UTILITY(U,$J,358.3,17674,2)
 ;;=^5001590
 ;;^UTILITY(U,$J,358.3,17675,0)
 ;;=C83.50^^65^769^105
 ;;^UTILITY(U,$J,358.3,17675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17675,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Unspec Site
